These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11265361)

  • 1. Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.
    Ward RP; Anderson AS
    Postgrad Med; 2001 Mar; 109(3):36-8, 41-5. PubMed ID: 11265361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [History of cardiology in the last 100 years: Heart and vasoactive substances].
    Kinoshita M
    Nihon Naika Gakkai Zasshi; 2002 Mar; 91(3):828-31. PubMed ID: 11985086
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacologic management of heart failure: neurohormonal agents.
    Moser DK
    Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure.
    Kubo SH
    Circulation; 1990 Feb; 81(2 Suppl):III107-14. PubMed ID: 2137052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuro-hormonal mechanisms in heart failure -- from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; da Faria DB
    Rev Port Cardiol; 2001 May; 20 Suppl 5():V-99-122; discussion V-123-5. PubMed ID: 11515306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuro-hormonal mechanisms in heart insufficiency--from physiopathology to treatment].
    Cerqueira-Gomes M; Polónia J; Brandão F; Ramalhão C; de Faria DB
    Rev Port Cardiol; 1989 Feb; 8(2):129-48. PubMed ID: 2576635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing patients with heart failure.
    Ammon S
    Am J Nurs; 2001 Dec; 101(12):34-40. PubMed ID: 12585064
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of vasopressin in congestive heart failure.
    Goldsmith SR
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S19-23. PubMed ID: 16970149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I; Liu P; Webb G
    Int J Cardiol; 2004 Dec; 97 Suppl 1():25-33. PubMed ID: 15590076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurohumoral blockade in CHF management.
    Willenbrock R; Philipp S; Mitrovic V; Dietz R
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():24-30. PubMed ID: 11967792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathophysiology of congestive heart failure].
    Luzza F; Bruni F; Rizzo F; Carerj S
    Minerva Cardioangiol; 2002 Jun; 50(3):209-19. PubMed ID: 12107401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based therapy for heart failure.
    Deedwania PC; Carbajal E
    Med Clin North Am; 2012 Sep; 96(5):915-31. PubMed ID: 22980055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
    Cleland JG; Morgan K
    Curr Opin Cardiol; 1996 May; 11(3):252-62. PubMed ID: 8835867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
    MMW Fortschr Med; 2005 Jul; 147(27-28):44. PubMed ID: 16041942
    [No Abstract]   [Full Text] [Related]  

  • 19. Hormones and hemodynamics in heart failure.
    Schrier RW; Abraham WT
    N Engl J Med; 1999 Aug; 341(8):577-85. PubMed ID: 10451464
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
    Moser DK; Biddle MJ
    Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.